Nordic Nanovector ASA – Recommendation of the Nomination Committee

Reference is made to the Notice of Annual General Meeting of Nordic Nanovector ASA (“Nordic Nanovector” or the “Company”) dated 23 February 2015.

Attached is the recommendation of the Company’s Nomination Committee regarding election of Board and Nomination Committee members, and remuneration for the members of the Board and the Nomination Committee.

About Nordic Nanovector

Nordic Nanovector is a biotech company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radio-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of Non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin™ comprises a tumor-seeking anti-CD37 antibody conjugated to low intensity radionuclide (Lutetium 177). It has shown promising efficacy in Phase 1 studies in a difficult-to-treat NHL patient population and as well as a very favourable tolerability. Betalutin™ is fast advancing through clinical development and with first approval anticipated in 2018.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialization of Betalutin™ in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat a number of select cancer indications.

www.nordicnanovector.com

This information was brought to you by Cision http://news.cision.com